2026 NPPES data Colon & Rectal Surgery Physician NPI 1417960550 M.D.
Verify on CMS →

MARK PIDALA, M.D.

Colon & Rectal Surgery Physician in HOUSTON, Texas. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
180
Medicare Part D claims · 85 beneficiaries · Colon & Rectal Surgery Physician avg: 196
Generic prescribing
84%
generic claims · 16% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
82.3883/100
▼ 1 pts below national avg 83.1 · [object Object]
Industry payments
$726.65
5 payments · CMS Open Payments (Sunshine Act)
What the federal data reveals: MARK PIDALA, M.D. is a Colon & Rectal Surgery Physician ([object Object]) practicing in HOUSTON, Texas with a Medicare Part D prescribing footprint of 180 claims across 85 beneficiaries — 16% brand-name prescribing . Their CMS MIPS Final Score of 82.3883/100 (national average: 83.1) reflects performance across Quality, Cost, Interoperability, and Improvement Activities . Industry payments of $726.65 across 5 transactions are disclosed under CMS Open Payments (Sunshine Act).

What stands out: MARK PIDALA, M.D. reported a CMS MIPS final score of 82.3883 out of 100, below the 83.1 national average, and filed 180 Medicare Part D claims in 2023. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

Board certification likely (heuristic — not verified)

MARK PIDALA, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

MARK PIDALA, M.D. at a glance

Near national average

NPI registry status

Active

Issued 08/13/2006

NPI 1417960550

Primary specialty

Colon & Rectal Surgery Physician

Niche

1,608 US NPIs in this specialty

Medicare Part D claims

180 8% vs specialty avg

2023 prescription claims

Specialty avg: 196

MIPS final score

82.3883/100 0.7116999999999933% pts

Above neutral band

vs 83.1 national avg

Specialty distribution in Texas

How Colon & Rectal Surgery Physician compares to other specialties among Texas providers

Texas providers

Colon & Rectal Surgery Physician share within Texas

1. Colon & Rectal Surgery Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Colon & Rectal Surgery Physician share within Texas

Medicare quality performance — MIPS

MARK PIDALA, M.D.'s 2023 MIPS final score plotted against the Colon & Rectal Surgery Physician national average

Near national average
MIPS Final Score
82.3883/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Colon & Rectal Surgery Physician) — 82.3883/100 vs national avg 83.1

0%100%National avg83%82.4%
MIPS final score (Colon & Rectal Surgery Physician) — 82.3883/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MARK PIDALA, M.D. is a Colon & Rectal Surgery Physician provider practicing in HOUSTON, Texas, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: M.D.. NPI: 1417960550. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

MARK PIDALA, M.D. appears in the CMS NPPES registry as a Colon & Rectal Surgery Physician provider holding M.D. credentials at 800 PEAKWOOD DR, HOUSTON, TX, 77090, with a listed phone of (713) 486-4650. NPI 1417960550 was issued on 08/13/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what PIDALA most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 180 prescription claims written by this provider, covering 85 Medicare beneficiaries and totaling roughly $12K in drug spend, split 16% brand-name and 84% generic by claim count, with an opioid prescribing rate of 17.2%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 82.3883/100 for the 2023 performance year (Quality 79.2344, Cost 58.5062), compared with the national average of 83.1.

Colon & Rectal Surgery Physician is a narrow specialty nationwide, with 1,608 enrolled providers across 50 states and an average of 196 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

800 PEAKWOOD DR
HOUSTON, TX 77090

Provider Details

NPI 1417960550
Specialty Colon & Rectal Surgery Physician
Credentials M.D.
Gender Male
NPI Issued 08/13/2006

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

82.3883
Final Score
Avg: 83.1
79.2344
Quality
58.5062
Cost
100
Promoting Interoperability

Reporting: Group practice

Hospital and facility affiliations

Facilities where MARK PIDALA, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

UT PHYSICIANS
SHENANDOAH, TX

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MARK PIDALA, M.D.. Source: openpaymentsdata.cms.gov.

Total received

$727

Largest payer

Baxter Healthcare

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Texas TMB 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 — they are NOT specific to MARK PIDALA, M.D.. To verify MARK PIDALA, M.D.'s current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

344
Total board actions, Texas 2023
Across 334 cases
4.47
Actions per 1,000 licensees
Texas statewide rate
probation
Most common action type
94 cases

TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Typical

MARK PIDALA, M.D. — brand share 16.0%
Specialty average (est.)

16% brand-name claims vs 84% generic, on 180 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

180
Total Claims
$12K
Total Drug Cost
85
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
191
Total Day Supply
2,406
Brand vs Generic
16% brand / 84% generic
Brand Drug Cost
$6K
Generic Drug Cost
$6K
Opioid Claims
31 (17.2% rate)
Antibiotic Claims
56

Patient Demographics

Average Patient Age
71.2 years
Avg HCC Risk Score
1.28
Gender Split
61% female / 39% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Metronidazole
22
Neomycin Sulfate
18
Colesevelam Hcl
17
Hydrocodone-Acetaminophen
Hydrocodone/Acetaminophen
16
Clenpiq
Sod Picosulf/Mag Ox/Citric Ac
15
Mesalamine
13
Dicyclomine Hcl
12

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Colon & Rectal Surgery Physician Overview

How MARK PIDALA, M.D. fits within the Colon & Rectal Surgery Physician landscape nationally.

1,608
Colon & Rectal Surgery Physician Providers in US
50
States with Colon & Rectal Surgery Physician
196
Avg Claims per Provider

MARK PIDALA, M.D.'s 180 claims are below the specialty average of 196.

Nearby Colon & Rectal Surgery Physician Providers in Texas

Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as PIDALA.

Compare Colon & Rectal Surgery Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is MARK PIDALA, M.D.'s specialty?
MARK PIDALA, M.D. specializes in Colon & Rectal Surgery Physician and practices in HOUSTON, Texas. Credentials: M.D..
How much does MARK PIDALA, M.D. prescribe under Medicare Part D?
In 2023, MARK PIDALA, M.D. wrote 180 Medicare Part D claims totaling $12K in drug costs for 85 beneficiaries.
What is MARK PIDALA, M.D.'s Medicare quality score?
MARK PIDALA, M.D. has a CMS MIPS Final Score of 82.3883/100 (Quality: 79.2344, Cost: 58.5062). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is MARK PIDALA, M.D. located?
MARK PIDALA, M.D. is located at 800 PEAKWOOD DR, HOUSTON, TX, 77090. Phone: (713) 486-4650.
What is MARK PIDALA, M.D.'s NPI number?
MARK PIDALA, M.D.'s National Provider Identifier (NPI) is 1417960550, issued on 08/13/2006.
Does MARK PIDALA, M.D. prescribe more brand-name or generic drugs?
MARK PIDALA, M.D.'s prescribing is 16% brand-name and 84% generic drugs by claim count, with $6K in brand drug costs.
Does MARK PIDALA, M.D. prescribe opioids?
Yes, MARK PIDALA, M.D. had 31 opioid claims in 2023 with an opioid prescribing rate of 17.2%.
How many Colon & Rectal Surgery Physician providers are there in the US?
There are 1,608 Colon & Rectal Surgery Physician providers across 50 states in the US. The average Colon & Rectal Surgery Physician provider writes 196 Medicare Part D claims per year.
What drugs does MARK PIDALA, M.D. prescribe most often?
Based on 2023 Medicare Part D data, MARK PIDALA, M.D.'s most frequently prescribed drugs include Metronidazole, Neomycin Sulfate, Colesevelam Hcl. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MARK PIDALA, M.D. accept Medicare?
MARK PIDALA, M.D. appears in CMS Medicare data with 180 Part D claims and 85 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MARK PIDALA, M.D.'s credentials?
MARK PIDALA, M.D.'s NPI is 1417960550 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology